Trial Profile
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 08 Feb 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Yttrium-90 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 03 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Jun 2023.
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium
- 31 Aug 2022 Planned End Date changed from 1 Jul 2022 to 1 Jan 2023.